The treatment landscape for hemophilia is changing fast, and today marks a turning point. The FDA has just cleared Roche to sell its drug emicizumab (Hemlibra) to patients with any form of hemophilia A—making it, potentially, the choice treatment for the disease. At least for now.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,